Search Results - "RUEFFER, U"

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group by Josting, Andreas, Rueffer, Ulrich, Franklin, Jeremy, Sieber, Markus, Diehl, Volker, Engert, Andreas

“…To determine prognostic factors and treatment outcome, patients with primary progressive Hodgkin lymphoma (HD) registered in the database of the German Hodgkin…”
Get full text

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment by Rueffer, U., Breuer, K., Josting, A., Lathan, B., Sieber, M., Manzke, O., Grotenhermen, F.-J., Tesch, H., Bredenfeld, H., Koch, P., Nisters-Backes, H., Wolf, J., Engert, A., Diehl, V.

“…Summary Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens…”
Get full text

14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group by SIEBER, M, BREDENFELD, H, SOEKLER, M, EICH, H, MÜLLER-HERMELINK, H. K, FRANKLIN, J, PAULUS, U, WOLF, J, ENGERT, A, DIEHL, V, JOSTING, A, REINEKE, T, RUEFFER, U, KOCH, T, NAUMANN, R, BOISSEVAIN, F, KOCH, P, WORST, P

“…This multicenter pilot study assessed the feasibility and efficacy of a time-intensified bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,…”
Get full text

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group by Diehl, V, Franklin, J, Hasenclever, D, Tesch, H, Pfreundschuh, M, Lathan, B, Paulus, U, Sieber, M, Rueffer, J U, Sextro, M, Engert, A, Wolf, J, Hermann, R, Holmer, L, Stappert-Jahn, U, Winnerlein-Trump, E, Wulf, G, Krause, S, Glunz, A, von Kalle, K, Bischoff, H, Haedicke, C, Duehmke, E, Georgii, A, Loeffler, M

“…The HD9 trial aims to evaluate whether moderate dose escalation and/or acceleration of standard polychemotherapy is beneficial for advanced-stage Hodgkin's…”
Get more information

Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial by Sieber, M., Tesch, H., Pfistner, B., Rueffer, U., Paulus, U., Munker, R., Hermann, R., Doelken, G., Koch, P., Oertel, J., Roller, S., Worst, P., Bischof, H., Glunz, A., Greil, R., von Kalle, K., Schalk, K. P., Hasenclever, D., Brosteanu, O., Duehmke, E., Georgii, A., Engert, A., Loeffler, M., Diehl, V.

“…Background: The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP…”
Get full text

Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis by RUEFFER, Ulrich, JOSTING, Andreas, FRANKLIN, Jeremy, MAY, Michael, SIEBER, Markus, BREUER, Kai, ENGERT, Andreas, HODGKIN, Volker Diehl For The, GROUP, S. Lymphoma

“…The cumulative incidence for non-Hodgkin lymphoma's (NHL) after primary Hodgkin's disease (HD) ranges between 1% and 6%. To investigate the course of disease…”
Get full text

Hodgkin's disease in the elderly: current status and future directions by Proctor, S. J., Rueffer, J. U., Angus, B., Breuer, K., Flechtner, H., Jarrett, R., Levis, A., Taylor, P., Tirelli, U.

“…In general, it was agreed that high rates of toxicities during treatment occur in the elderly and that there is a frequent occurrence of early relapse. It is…”
Get full text

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM) by Josting, A., Kátay, I., Rueffer, U., Winter, S., Tesch, H., Engert, A., Diehl, V., Wickramanayake, P. D.

“…Background: Disease status before high-dose chemotherapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation…”
Get full text

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group by Pfreundschuh, M G, Rueffer, U, Lathan, B, Schmitz, N, Brosteanu, O, Hasenclever, D, Haas, R, Kirchner, H, Koch, P, Kuse, R

“…A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage…”
Get more information

Spleen involvement in Hodgkin's lymphoma: assessment and risk profile by RUEFFER, U, SIEBER, M, STEMBERG, M, GOSSMANN, A, JOSTING, A, KOCH, T, GROTENHERMEN, F, DIEHL, V

“…Diagnostic laparotomy is no longer routinely performed in Hodgkin's lymphoma and noninvasive diagnosis of spleen involvement remains uncertain. In order to…”
Get full text

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994 by Greil, R, Holzner, B, Kemmler, G, Kopp, M, Buchowski, A, Oberaigner, W, Fritsch, E, Dirnhofer, S, Rueffer, U, Diehl, V, Sperner-Unterweger, B

“…We determined the current quality of life (QoL) of patients with Hodgkin's disease treated at the Innsbruck University Hospital between 1969 and 1994 at a mean…”
Get full text

Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF by Pfreundschuh, M., Hasenclever, D., Loeffler, M., Ehninger, G., Schmitz, N., Kirchner, H., Koch, P., Lathan, B., Rueffer, U., Sextro, M., Franklin, J., Tesch, H., Diehl, V.

“…Background The magnitude of chemotherapy dose escalation made possible by the use of recombinant haematopoietic growth factors has not been quantified in a…”
Get full text

Prognostic factors for subdiaphragmatic involvement in clinical stage I–II supradiaphragmatic Hodgkin's disease: A retrospective analysis of the GHSG by Rueffer, U., Sieber, M., Josting, A., Breuer, K., Grotenhermen, F. J., Bredenfeld, H., Tesch, H., Nisters-Backes, H., Engert, A., Diehl, V.

“…Background: Staging laparotomy and splenectomy were routinely performed in patients with early-stage Hodgkin's disease (HD) qualifying for radiotherapy alone…”
Get full text

Dexamethasone, Carmustine, Etoposide, Cytarabine, and Melphalan (Dexa-BEAM) Followed by High-Dose Chemotherapy and Stem Cell Rescue - A Highly Effective Regimen for Patients with Refractory or Relapsed Indolent Lymphoma by Josting, A., Reiser, M., Wickramanayake, P. Dias, Rueffer, U., Draube, A., Söhngen, D., Tesch, H., Wolf, J., Diehl, V., Engert, A.

“…We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU],…”
Get full text

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group by Josting, Andreas, Rueffer, Ulrich, Franklin, Jeremy, Sieber, Markus, Diehl, Volker, Engert, Andreas

“…To determine prognostic factors and treatment outcome, patients with primary progressive Hodgkin lymphoma (HD) registered in the database of the German Hodgkin…”
Get full text

Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure? by JOSTING, A, REISER, M, RUEFFER, U, SALZBERGER, B, DIEHL, V, ENGERT, A

“…To determine differences in prognosis between primary progressive Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL), we retrospectively…”
Get full text

Self-reported fatigue in patients with rheumatoid arthritis compared to patients with cancer: results from two large-scale studies by Müller, Karolina, Kuipers, Jens G., Weis, Joachim, Fischer, Irene, Pukrop, Tobias, Rüffer, Jens U., Koller, Michael

“…Fatigue is a common symptom in patients with rheumatoid arthritis (RA) and in patients with cancer (CA). The aim was to investigate the degree of fatigue in RA…”
Get full text

Adherence and health literacy as related to outcome of patients treated for rheumatoid arthritis: Analyses of a large-scale observational study by Kuipers, J. G., Koller, M., Zeman, F., Müller, K., Rüffer, J. U.

“…Background Disabilities in daily living and quality of life are key endpoints for evaluating the treatment outcome for rheumatoid arthritis (RA). Factors…”
Get full text

Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin’s Lymphoma: Final Results of the German Hodgkin’s Lymphoma Study Group Trial HD5 by Sieber, M.

Get full text

Tumorassoziierte Fatigue beim Hodgkin-Lymphom by Kreissl, S., Bürkle, C., Rüffer, U., Mehnert, A., Borchmann, P.

“…Zusammenfassung Hintergrund Da heutzutage die meisten Hodgkin-Patienten geheilt werden können, ist die Nachsorge der überwiegend jungen Langzeitüberlebenden in…”
Get full text